241 related articles for article (PubMed ID: 36533232)
1. Novel use of riociguat in infants with severe pulmonary arterial hypertension unable to wean from inhaled nitric oxide.
Domingo LT; Ivy DD; Abman SH; Grenolds AM; MacLean JT; Breaux JA; Minford KJ; Frank BS
Front Pediatr; 2022; 10():1014922. PubMed ID: 36533232
[TBL] [Abstract][Full Text] [Related]
2. First-in-child use of the oral soluble guanylate cyclase stimulator riociguat in pulmonary arterial hypertension.
Spreemann T; Bertram H; Happel CM; Kozlik-Feldmann R; Hansmann G
Pulm Circ; 2018; 8(1):2045893217743123. PubMed ID: 29099661
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with riociquat and inhaled treprostinil in inoperable and progressive chronic thromboembolic pulmonary hypertension.
Swisher JW; Elliott D
Respir Med Case Rep; 2017; 20():45-47. PubMed ID: 27942445
[TBL] [Abstract][Full Text] [Related]
4. Successful Transition From Phosphodiesterase-5 Inhibitors to Riociguat Without a Washout Period in Patients With Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension: A Pilot Cohort Study.
Kuroda K; Akagi S; Nakamura K; Sarashina T; Ejiri K; Ito H
Heart Lung Circ; 2020 Mar; 29(3):331-336. PubMed ID: 30773322
[TBL] [Abstract][Full Text] [Related]
5. Switching from sildenafil to riociguat for the treatment of PAH and inoperable CTEPH: Real-life experiences.
Andersen A; Korsholm K; Mellemkjær S; Nielsen-Kudsk JE
Respir Med Case Rep; 2017; 22():39-43. PubMed ID: 28652963
[TBL] [Abstract][Full Text] [Related]
6. Early Observations on the Use of Riociguat in a Large, Metropolitan Pulmonary Arterial Hypertension/Chronic Thromboembolic Pulmonary Hypertension Treatment Center.
Sulica R; Fenton R; Cefali F
Cardiol Ther; 2015 Dec; 4(2):209-18. PubMed ID: 26411969
[TBL] [Abstract][Full Text] [Related]
7. Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors.
Hoeper MM; Klinger JR; Benza RL; Simonneau G; Langleben D; Naeije R; Corris PA
Respir Med; 2017 Jan; 122 Suppl 1():S18-S22. PubMed ID: 27887774
[TBL] [Abstract][Full Text] [Related]
8. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
Hoeper MM; Al-Hiti H; Benza RL; Chang SA; Corris PA; Gibbs JSR; Grünig E; Jansa P; Klinger JR; Langleben D; McLaughlin VV; Meyer GMB; Ota-Arakaki J; Peacock AJ; Pulido T; Rosenkranz S; Vizza CD; Vonk-Noordegraaf A; White RJ; Chang M; Kleinjung F; Meier C; Paraschin K; Ghofrani HA; Simonneau G;
Lancet Respir Med; 2021 Jun; 9(6):573-584. PubMed ID: 33773120
[TBL] [Abstract][Full Text] [Related]
9. Riociguat: a novel new drug for treatment of pulmonary hypertension.
Makowski CT; Rissmiller RW; Bullington WM
Pharmacotherapy; 2015 May; 35(5):502-19. PubMed ID: 26011143
[TBL] [Abstract][Full Text] [Related]
10. Acute pulmonary vasodilator testing with inhaled treprostinil in children with pulmonary arterial hypertension.
Takatsuki S; Parker DK; Doran AK; Friesen RH; Ivy DD
Pediatr Cardiol; 2013 Apr; 34(4):1006-12. PubMed ID: 23184020
[TBL] [Abstract][Full Text] [Related]
11. Case report: Rescue treatment with add-on selexipag in a preterm infant with suprasystemic pulmonary hypertension, pulmonary capillary hemangiomatosis, and isolated pulmonary vein stenosis.
Hasan H; Hysko K; Jack T; Dingemann J; Wetzke M; Hansmann G
Front Cardiovasc Med; 2022; 9():984698. PubMed ID: 36568561
[TBL] [Abstract][Full Text] [Related]
12. Intravenous sildenafil and inhaled nitric oxide: a randomised trial in infants after cardiac surgery.
Stocker C; Penny DJ; Brizard CP; Cochrane AD; Soto R; Shekerdemian LS
Intensive Care Med; 2003 Nov; 29(11):1996-2003. PubMed ID: 14530859
[TBL] [Abstract][Full Text] [Related]
13. Inhaled NO and sildenafil combination in cardiac surgery patients with out-of-proportion pulmonary hypertension: acute effects on postoperative gas exchange and hemodynamics.
Matamis D; Pampori S; Papathanasiou A; Papakonstantinou P; Tsagourias M; Galiatsou E; Koulouras V; Nakos G
Circ Heart Fail; 2012 Jan; 5(1):47-53. PubMed ID: 22057829
[TBL] [Abstract][Full Text] [Related]
14. Riociguat: a soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
Lian TY; Jiang X; Jing ZC
Drug Des Devel Ther; 2017; 11():1195-1207. PubMed ID: 28458514
[TBL] [Abstract][Full Text] [Related]
15. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Bishop BM
Am J Health Syst Pharm; 2014 Nov; 71(21):1839-44. PubMed ID: 25320133
[TBL] [Abstract][Full Text] [Related]
16. Acute haemodynamic responses to inhaled nitric oxide and intravenous sildenafil in distal chronic thromboembolic pulmonary hypertension (CTEPH).
Suntharalingam J; Hughes RJ; Goldsmith K; Doughty N; George P; Toshner M; Sheares KK; Pepke-Zaba J
Vascul Pharmacol; 2007 Jun; 46(6):449-55. PubMed ID: 17368113
[TBL] [Abstract][Full Text] [Related]
17. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension.
Grimminger F; Weimann G; Frey R; Voswinckel R; Thamm M; Bölkow D; Weissmann N; Mück W; Unger S; Wensing G; Schermuly RT; Ghofrani HA
Eur Respir J; 2009 Apr; 33(4):785-92. PubMed ID: 19129292
[TBL] [Abstract][Full Text] [Related]
18. Riociguat, an oral soluble guanylate cyclase stimulator for the treatment of pulmonary hypertension.
Belik J
Curr Opin Investig Drugs; 2009 Sep; 10(9):971-9. PubMed ID: 19705340
[TBL] [Abstract][Full Text] [Related]
19. Comparison of intravenous sildenafil with inhaled nitric oxide for acute vasodilator testing in pulmonary arterial hypertension.
Kumar S; Memon D; Raj M; Sen AC; Jayasankar JP; Leeladharan SP; Sudhakar A; Kumar RK
Pulm Circ; 2022 Oct; 12(4):e12180. PubMed ID: 36583117
[TBL] [Abstract][Full Text] [Related]
20. Use of sildenafil to facilitate weaning from inhaled nitric oxide in children with pulmonary hypertension following surgery for congenital heart disease.
Lee JE; Hillier SC; Knoderer CA
J Intensive Care Med; 2008; 23(5):329-34. PubMed ID: 18701525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
